India Pharma - IPM Growth In June Stabilises At 14%: Anand Rathi
Colourful capsules strips. (Photograph: Bloomberg)

India Pharma - IPM Growth In June Stabilises At 14%: Anand Rathi


BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Anand Rathi Report

Fewer Covid-19 cases in the country have led to the India pharma market growth normalising to 14.1% in June 2021.

The sector continues to benefit from Covid-drug sales, but this will start fading in coming months if the country tackles/avoids the third wave.

Key Covid-19 molecules (remdesivir, June sales Rs 408 million; favipiravir, Rs 465 million) have declined month-on-month, respectively 47% and 80%.

June volume-driven growth was 4%, price 5.7%, and 4.4% from launches.

Acute therapy sales in June grew a strong 20.6%, while chronic and sub-chronic therapies grew 7.8% and 11.2% respectively.

For Q1 FY22 the sector grew a robust 37%: 23% volume-driven, 6.5% price-driven and 7.7% from launches.

Click on the attachment to read the full report:

Anand Rathi India Pharma Monthly Update.pdf


This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.